Copyright Reports & Markets. All rights reserved.

Global Homozygous Familial Hypercholesterolemia Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Homozygous Familial Hypercholesterolemia Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Product
      • 1.4.2 AEM-2802
      • 1.4.3 AEM-2814
      • 1.4.4 Alirocumab
      • 1.4.5 Evinacumab
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size
      • 2.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue 2014-2025
      • 2.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales 2014-2025
    • 2.2 Homozygous Familial Hypercholesterolemia Treatment Growth Rate by Regions
      • 2.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Regions
      • 2.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers
      • 3.1.1 Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers
      • 3.1.2 Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Homozygous Familial Hypercholesterolemia Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers
      • 3.2.1 Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Homozygous Familial Hypercholesterolemia Treatment Price by Manufacturers
    • 3.4 Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Homozygous Familial Hypercholesterolemia Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Homozygous Familial Hypercholesterolemia Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Homozygous Familial Hypercholesterolemia Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Product
    • 4.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Product
    • 4.3 Homozygous Familial Hypercholesterolemia Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Homozygous Familial Hypercholesterolemia Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Homozygous Familial Hypercholesterolemia Treatment by Countries
      • 6.1.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Countries
      • 6.1.2 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Homozygous Familial Hypercholesterolemia Treatment by Product
    • 6.3 North America Homozygous Familial Hypercholesterolemia Treatment by End User

    7 Europe

    • 7.1 Europe Homozygous Familial Hypercholesterolemia Treatment by Countries
      • 7.1.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Countries
      • 7.1.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Homozygous Familial Hypercholesterolemia Treatment by Product
    • 7.3 Europe Homozygous Familial Hypercholesterolemia Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment by Countries
      • 8.1.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Countries
      • 8.1.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment by Product
    • 8.3 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Homozygous Familial Hypercholesterolemia Treatment by Countries
      • 9.1.1 Central & South America Homozygous Familial Hypercholesterolemia Treatment Sales by Countries
      • 9.1.2 Central & South America Homozygous Familial Hypercholesterolemia Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Homozygous Familial Hypercholesterolemia Treatment by Product
    • 9.3 Central & South America Homozygous Familial Hypercholesterolemia Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment by Countries
      • 10.1.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment by Product
    • 10.3 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment by End User

    11 Company Profiles

    • 11.1 CymaBay Therapeutics Inc
      • 11.1.1 CymaBay Therapeutics Inc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
      • 11.1.5 CymaBay Therapeutics Inc Recent Development
    • 11.2 Daewoong Co Ltd
      • 11.2.1 Daewoong Co Ltd Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Products Offered
      • 11.2.5 Daewoong Co Ltd Recent Development
    • 11.3 Gemphire Therapeutics Inc
      • 11.3.1 Gemphire Therapeutics Inc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
      • 11.3.5 Gemphire Therapeutics Inc Recent Development
    • 11.4 LipimetiX Development Inc
      • 11.4.1 LipimetiX Development Inc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
      • 11.4.5 LipimetiX Development Inc Recent Development
    • 11.5 Regeneron Pharmaceuticals Inc
      • 11.5.1 Regeneron Pharmaceuticals Inc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
      • 11.5.5 Regeneron Pharmaceuticals Inc Recent Development
    • 11.6 RegenxBio Inc
      • 11.6.1 RegenxBio Inc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
      • 11.6.5 RegenxBio Inc Recent Development
    • 11.7 The Medicines Company
      • 11.7.1 The Medicines Company Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Products Offered
      • 11.7.5 The Medicines Company Recent Development

    12 Future Forecast

    • 12.1 Homozygous Familial Hypercholesterolemia Treatment Market Forecast by Regions
      • 12.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Homozygous Familial Hypercholesterolemia Treatment Market Forecast by Product
      • 12.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Homozygous Familial Hypercholesterolemia Treatment Market Forecast by End User
    • 12.4 North America Homozygous Familial Hypercholesterolemia Treatment Forecast
    • 12.5 Europe Homozygous Familial Hypercholesterolemia Treatment Forecast
    • 12.6 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Forecast
    • 12.7 Central & South America Homozygous Familial Hypercholesterolemia Treatment Forecast
    • 12.8 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Homozygous Familial Hypercholesterolemia Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Homozygous Familial Hypercholesterolemia Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Homozygous Familial Hypercholesterolemia Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Homozygous Familial Hypercholesterolemia Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Homozygous Familial Hypercholesterolemia Treatment in these regions.
      This research report categorizes the global Homozygous Familial Hypercholesterolemia Treatment market by top players/brands, region, type and end user. This report also studies the global Homozygous Familial Hypercholesterolemia Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      CymaBay Therapeutics Inc
      Daewoong Co Ltd
      Gemphire Therapeutics Inc
      LipimetiX Development Inc
      Regeneron Pharmaceuticals Inc
      RegenxBio Inc
      The Medicines Company

      Market size by Product
      AEM-2802
      AEM-2814
      Alirocumab
      Evinacumab
      Others
      Market size by End User
      Clinic
      Hospital
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Homozygous Familial Hypercholesterolemia Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Homozygous Familial Hypercholesterolemia Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Homozygous Familial Hypercholesterolemia Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Homozygous Familial Hypercholesterolemia Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Homozygous Familial Hypercholesterolemia Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Homozygous Familial Hypercholesterolemia Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now